Heritage Investors Management Corp Sells 15,875 Shares of Merck & Co., Inc. $MRK

Heritage Investors Management Corp cut its position in shares of Merck & Co., Inc. (NYSE:MRK) by 4.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 316,592 shares of the company’s stock after selling 15,875 shares during the period. Merck & Co., Inc. accounts for approximately 1.1% of Heritage Investors Management Corp’s holdings, making the stock its 24th largest holding. Heritage Investors Management Corp’s holdings in Merck & Co., Inc. were worth $40,682,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $26,000. High Note Wealth LLC boosted its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $31,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Merck & Co., Inc. Trading Up 2.3%

MRK opened at $152.43 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $154.49. The stock has a market cap of $376.07 billion, a PE ratio of 121.94, a PEG ratio of 6.43 and a beta of 0.19. The business has a 50 day moving average of $128.09 and a 200-day moving average of $121.23.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 272.00%.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Citigroup initiated coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target on the stock. Royal Bank Of Canada cut shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and raised their target price for the stock from $142.00 to $150.00 in a report on Thursday. Barclays lifted their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. upped their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Finally, Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.10.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Michael Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.